Alunbrig OverviewBrigatinib (INN, previously known as AP26113, marketed as Alunbrig) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). In 28 April 2017, it was granted an Accelerated Approval from the US FDA for metastatic non-small cell lung cancer (NSCLC); as a 2nd-line therapy for ALK-positive NSCL...
Read more Alunbrig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brigatinib
Recent Alunbrig Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 30mg, 90mg
NDC Database Records for Alunbrig: (1 result)Sorted by National Drug Code
- 76189-113 Alunbrig 30 mg Oral Tablet, Coated by Ariad Pharmaceuticals Inc.